Coenzyme Q10 and statins: what the evidence on ubiquinol shows
Statins lower the coenzyme Q10 level in your blood. That part is supported. Whether the muscle pain comes from it is the open question. Here is the evidence without sugar-coating and without panic.
There are two loud camps around coenzyme Q10. One says every statin needs Q10 alongside it. The other says Q10 is a waste of money. Both talk louder than the data allows. Between the camps lies a narrow, honest corridor. That is exactly where I want to walk with you.
You have been on a statin for a few months. Your cholesterol has come down, your doctor is pleased. Except your thighs feel as though you climbed stairs yesterday that were never there.
You type that into your phone at night. And within two minutes you find the answer everyone gives: coenzyme Q10. Preferably as ubiquinol, said to be the active form. Sounds logical. Almost too logical.
I understand the pull of that explanation very well. It is biochemically clean, it explains your symptom, and it offers a solution you can order online. That is exactly why I look at it so closely.
The short answer up front: one part of this story is well supported. Another part is open. And a third part is a misunderstanding that can become dangerous. Let us sort it out.
What you will find here
- Why statins touch coenzyme Q10 of all things
- What Q10 actually does inside the mitochondrion
- How strong the evidence for the drop in blood levels is
- Why the meta-analyses on muscle pain contradict each other
- What the nocebo effect genuinely contributes here
- Ubiquinone or ubiquinol, compared soberly
- Heart, blood pressure, migraine, fertility, each with its evidence level
- The safety questions nobody is allowed to skip
Why statins and coenzyme Q10 end up in the same sentence at all
Start with a picture. Imagine a factory with a single conveyor belt. Raw material is fed in at the very front. Further back the belt splits into several end products.
One of those end products is cholesterol. Another is coenzyme Q10. A third is a set of small tags the cell uses to pin certain control proteins to its membrane.
This conveyor belt is called the mevalonate pathway. And a statin does not block it at the end, it blocks it right at the front, at an enzyme called HMG-CoA reductase. That is the switch point where the factory decides how much raw material gets onto the belt in the first place.
With that, the core of the whole debate is already explained. Whoever throttles the front does not throttle only one product. They throttle everything that branches off behind it.
A research group in preventive cardiology at Hartford Hospital worked through the Q10 hypothesis in statin muscle symptoms systematically. They describe the point very precisely: statins block the formation of farnesyl pyrophosphate, an intermediate of the mevalonate pathway. The tail of the coenzyme Q10 molecule is built from exactly that intermediate.
From this comes the hypothesis that a fall in coenzyme Q10 could contribute to the muscle symptoms. The authors explicitly call the idea plausible.
And in the same breath they name the problem: the studies meant to test this hypothesis reach contradictory results. Their title says it all: a good idea, but.
Zaleski AL et al. Adv Nutr. 2018. DOI: 10.1093/advances/nmy010Right at the start there is a lesson here that goes well beyond coenzyme Q10. The body regulates its building blocks in networks, not in single lines. Turn one screw and you move others with it. With a statin that is neither an accident nor a flaw, it is the unavoidable consequence of several products sharing one origin.
A nutrient is not a switch. It is a player in a network that keeps rebalancing itself.
So the question is never only “does Q10 do anything". The question is always: what else moves when I intervene here?
And now you know why statins and coenzyme Q10 belong together biochemically, long before anyone sold a single capsule.
What coenzyme Q10 actually does inside the mitochondrion
Before we talk about studies, I want to show you what this is about. Otherwise Q10 stays a word on a tin.
Inside every one of your cells sit mitochondria. In their inner membrane runs the respiratory chain, a row of large protein complexes that pass electrons along like a bucket chain at a fire. At the end of that chain comes the energy your body uses to build ATP.
Between the large complexes there are gaps. And that is exactly where coenzyme Q10 works. It is the ferryman who carries the electrons from one bank to the other. Without a ferry the bucket chain stands still, no matter how well the complexes work.
That explains why coenzyme Q10 sits most densely where the most energy is needed: in the heart muscle, in skeletal muscle, in liver and kidney.
A Spanish and American research group gathered the state of knowledge on coenzyme Q10. They describe two functions that belong together.
First, electron transport in the respiratory chain, without which the cell can barely make ATP. Second, the role as a fat-soluble antioxidant in cell membranes and in lipoproteins. Coenzyme Q10 is one of the few antioxidants the body makes itself that can work directly in a fatty environment.
They also note this: coenzyme Q10 is produced endogenously in all cells through a tightly regulated pathway. It is not a classic nutrient from outside. With age and in several chronic diseases, lower tissue levels have been measured. Whether that is cause or consequence is not settled by those measurements.
Hernández-Camacho JD et al. Front Physiol. 2018. DOI: 10.3389/fphys.2018.00044And here comes the turn that puts the whole ubiquinol marketing argument into perspective.
Ubiquinone and ubiquinol are not two different substances. They are two states of the same molecule. Ubiquinone is the oxidised form, ubiquinol the reduced one, the one carrying two extra electrons. The constant switch between the two states is not a drawback you would want to bypass. It is the function.
The ferry has to be loaded and unloaded again, otherwise it does not sail. Ubiquinone and ubiquinol are the same ferry, once full and once empty.
For nutrition this means something unusual. For coenzyme Q10 there is no official reference value for daily intake of the kind vitamins have. The reason is simple: the body makes by far the largest share itself. Comparatively little comes in through food, mostly from organ meats, from small oily fish such as sardine and herring, from nuts and oils.
That makes coenzyme Q10 a borderline case between nutrient and metabolic product. And this special position is why the usual rules of supplementation do not apply cleanly here.
With coenzyme Q10 too, the sentence I repeat in every one of these articles holds: a supplement does not replace food, sleep, movement, sunlight or relationships that carry you.
What sets coenzyme Q10 apart from the usual frame is your own synthesis. No plate in the world delivers as much of it as your own cells do. So anyone who wants to work on this sensibly starts with the conditions your mitochondria are working under, and only then reaches for a capsule.
And now you know why the ubiquinol question is smaller than the price gap on the shelf suggests.
Statins lower the Q10 level in blood: this part is well supported
Now to the part of the story that stands solidly. It often gets lost in discussions, because everyone is busy arguing about the contested part.
If you measure coenzyme Q10 in blood while on a statin, you find less of it on average than before. That is not a single finding and not a practice observation. Several research groups have compiled it independently from placebo-controlled trials.
An international working group led by a Polish lipidologist evaluated eight placebo-controlled study arms and calculated how far the coenzyme Q10 level in plasma falls under statins.
The result: on average 0.44 micromoles per litre less than under placebo, with a tight confidence interval of 0.37 to 0.52. The effect showed up with all four statins examined, with the fat-loving ones as well as the water-loving ones, and in shorter as well as longer treatment periods.
For context: reviews name a plasma range of roughly 0.40 to 1.91 micromoles per litre for healthy adults. The figure of 0.44 is a mean difference between two groups, however, not the distance of any single person from the lower limit. How many people on a statin actually drop into a low range is not something the data says. The authors themselves write that the clinical meaning of this fall still has to be clarified.
Banach M et al. Pharmacol Res. 2015. DOI: 10.1016/j.phrs.2015.07.008 · Bhagavan HN, Chopra RK. Free Radic Res. 2006. DOI: 10.1080/10715760600617843A second, later working group came to the same picture with a larger data base. Twelve randomised trials, 1,776 participants in total, the same direction. There too the drop showed up regardless of whether the statin was fat-loving or water-loving and whether the dose was low or high.
Here an important caveat is needed, one that serious authors raise themselves. The level in blood is not the level in muscle. Coenzyme Q10 travels through blood inside lipoproteins, that is, in the very transport particles a statin is designed to reduce. Part of the measured drop could therefore come down to fewer transport vehicles being on the road, not to cells holding less Q10.
Fewer ferries in the harbour does not automatically mean fewer ferries on the river.
I consider this objection important, because it shows how quickly a measured value turns into a story. And how rarely that story is checked.
A group in Nevada worked with myotubes, that is, muscle cells grown in the lab from a mouse cell line. They exposed the cells to high-dose simvastatin.
The cells lost viability, the coenzyme Q content in their mitochondria fell, and the oxygen consumption of the cells went down. When mevalonic acid was added at the same time, meaning the product downstream of the blocked enzyme, these effects did not appear. When coenzyme Q was added in a special water-soluble carrier form, mitochondrial Q values rose again and the cells survived better.
Important for context: this is cell culture with very high statin concentrations, not a treatment in people. The experiment shows that the suspected mechanism can work in principle. It does not prove that it is running in your thigh.
Moschetti A et al. Nanomedicine. 2021. DOI: 10.1016/j.nano.2021.102439And now you know why I stay calm about the first part of the story: the drop in levels is a fact. Everything that comes after it is interpretation.
Whether the muscle symptoms follow from that is the open question
Now comes the section where I will probably disappoint you. I am writing it anyway, because I do not want to hand you a text that only confirms what you hoped to hear.
If statins lower the Q10 level, and if Q10 is central to muscle energy, then giving Q10 should improve the muscle symptoms. That is the chain of reasoning. It has been tested in several randomised trials. And the results point in different directions.
A Chinese working group pooled twelve randomised trials with 575 participants and found less muscle pain, less weakness, fewer cramps and less muscle fatigue under coenzyme Q10 than under placebo. The muscle enzyme creatine kinase did not change.
An Irish and British group evaluated seven randomised trials with 321 participants and found no benefit, neither on pain nor on whether people kept taking their statin. Only two of the eight trials they screened had shown a positive effect at all.
A German working group from Giessen presented the most recent evaluation in 2025: seven randomised trials, 389 participants, daily doses between 100 and 600 mg over 30 to 90 days. Four trials showed an improvement, three did not. Pooled, there was a statistically significant but narrow advantage on pain. Their own conclusion: evidence-based recommendations need more research.
Qu H et al. J Am Heart Assoc. 2018. DOI: 10.1161/JAHA.118.009835 · Kennedy C et al. Atherosclerosis. 2020. DOI: 10.1016/j.atherosclerosis.2020.03.006 · Kovacic S et al. J Nutr Sci. 2025. DOI: 10.1017/jns.2025.10043Three meta-analyses, largely the same pool of trials, different conclusions. That is not a scandal, that is the normal state of affairs with small studies and soft endpoints. When pain is measured on a scale from zero to ten and the groups hold 35 to 76 people each, the choice of which trials to include helps decide what comes out at the end.
One of the most careful single trials is especially instructive here.
A group at Hartford Hospital did something most studies leave out. They first checked whether the symptoms came from the statin at all.
120 people with previous statin muscle pain went through eight weeks of blinded switching between simvastatin 20 mg and placebo. Only 41 of them developed pain on the statin and not on placebo. In their conclusion the authors sum that up as roughly a third of those affected. Those 41 were then randomised to 600 mg ubiquinol daily or placebo, for eight weeks each on top of the statin.
The coenzyme Q10 level in serum rose under ubiquinol from 1.3 to 5.2 micrograms per millilitre, so the preparation clearly arrived. The pain scores did not improve all the same, and muscle strength and maximum oxygen uptake did not change either.
One detail belongs here because it points the other way: in the ubiquinol group marginally more people reported pain than on placebo, 14 of 20 against 7 of 18, right at the edge of statistical significance. With numbers this small that is not evidence of harm. But it does not fit the assumption that adding it on top is neutral by default.
Taylor BA et al. Atherosclerosis. 2015. DOI: 10.1016/j.atherosclerosis.2014.12.016This trial matters for two reasons. First: the level rose fourfold and the symptoms stayed. That argues against a low Q10 level being the driving factor in these people.
Second, and this is the genuinely large finding: of 120 people who were sure their statin was causing the pain, the blinded test confirmed it in only about a third.
That does not mean the pain was imagined. It was real, measurable, wearing. It only means: in two out of three people it did not come from the statin.
Pain is genuine even when the suspected cause is not. That distinction is not an insult. It is the road to the right cause.
A limitation that belongs here: the rare, serious form
- Without this limitation the section would be dishonest. There is a rare but serious form: an immune-mediated muscle inflammation that can occur under statins and that does not resolve on its own after stopping.
- It shows up as increasing weakness in the thighs and upper arms rather than through pain, and the muscle enzyme creatine kinase can be markedly raised.
- If your symptoms increase over weeks, if you genuinely get weaker standing up or climbing stairs, or if they persist after a medically supervised pause, then creatine kinase belongs measured and the matter belongs investigated further.
- Everything I write in this chapter about expectation effects expressly does not apply to that constellation.
What the nocebo effect contributes here
This is where it gets fascinating. Two British research groups independently did something unusual: they asked the question not in groups, but in each person individually, repeatedly, and blinded.
A group at Imperial College London gave 60 people who had stopped their statin because of side effects twelve monthly bottles: four with atorvastatin 20 mg, four with placebo, four empty. Participants rated their symptoms daily through an app.
In the empty months the symptom score was 8.0. In the statin months it was 16.3. And in the placebo months 15.4, so practically as high as on the statin. The ratio the researchers calculated as the nocebo quotient came to 0.90. Six months after the trial, half of the participants were taking a statin again.
A second group at the London School of Hygiene and Tropical Medicine ran 200 such individual trials in parallel across 50 general practices, each over six treatment blocks of two months. There too no difference was found between statin and placebo, the mean difference was minus 0.11 on a scale from zero to ten.
Howard JP et al. J Am Coll Cardiol. 2021. DOI: 10.1016/j.jacc.2021.07.022 · Herrett E et al. BMJ. 2021. DOI: 10.1136/bmj.n135I want to put this very carefully, because the topic can easily sound disrespectful. Nocebo does not mean imagination. It means that expectation, attention and meaning help decide how strongly a body signal is perceived. That is neurobiology, not a judgement of character.
And it means something else too. If a large share of the symptoms does not arise pharmacologically, then a supplement aimed at the pharmacological mechanism can do little in many cases. That explains part of the contradictory study results better than any discussion about dose or formulation.
Here ends what studies show reliably. What I observe clinically goes further, and I say deliberately that it is an observation without a control group: in people with muscle symptoms on statins I often find something else as well. A low vitamin D status. An unrecognised underactive thyroid. Years of little movement and then suddenly a lot.
Whether these findings have anything to do with the symptoms is not settled by that. Which values make sense for you is decided by the doctor treating you, and that can also mean: none.
And now you know why I hesitate at “just take Q10 alongside" without throwing the idea away.
Ubiquinone or ubiquinol: what the difference is worth
You are standing in front of two tins. One says coenzyme Q10. The other says ubiquinol, advertised as the active form, and it usually costs considerably more. Now what?
The sales logic is catchy: ubiquinol is said to be the active form, the body supposedly has to convert ubiquinone first, and with age that conversion is said to get harder. Sounds coherent. The data is more reserved. Whether that surcharge buys anything cannot be answered with the data available. In the only direct comparison study in older people known to me, and it covered just 21 individuals, the difference was not statistically secure. That is not evidence against ubiquinol, it is missing evidence for it.
A Slovenian and Spanish working group tested exactly this question in 21 healthy people between 65 and 74 years old, in a randomised cross-over design with a one-week washout between preparations. All three formulations contained 100 mg of coenzyme Q10.
Result: a water-soluble syrup formulation reached 2.4 times the uptake of standard ubiquinone and was statistically superior. Ubiquinol capsules reached 1.7 times, and this difference was not statistically secure, with a confidence interval running from 0.9 to 3.1.
And one side finding that puts the whole debate into perspective: the redox state of the absorbed coenzyme Q10 did not differ between the forms. It appeared in blood predominantly as ubiquinol, even when it had been swallowed as ubiquinone.
Pravst I et al. Nutrients. 2020. DOI: 10.3390/nu12030784This side finding matches what reviews have described for a long time: around 95 percent of the coenzyme Q10 circulating in blood is present as ubiquinol, and that ratio barely shifts through what you swallow. The body largely regulates the redox state itself.
One note for context that I consider mandatory: a considerable share of the bioavailability data on coenzyme Q10 comes from investigations by authors with manufacturer ties. The most reliable of these reviews states exactly that in its author disclosures. That does not make the data wrong. It only means that any formulation advertised as superior deserves an extra portion of scepticism.
And for completeness, because I want to apply the same standard everywhere: in the cross-over study just described, the water-soluble syrup formulation was the investigational product, and it came from the authors' own circle. That does not make the result wrong. It only means that this finding too needs independent repetition before it becomes a shopping rule.
Ubiquinone
The oxidised form, used in most studies, considerably cheaper. In the body it is largely converted to ubiquinol.
Downside: a large, strongly fat-loving molecule, so uptake in the gut is slow and limited. Without fat in the meal, little can arrive.
Ubiquinol
The reduced form. In theory it saves the body one conversion step.
Open: in the direct comparison in older people the advantage was not statistically secure, though the study covered only 21 individuals. Ubiquinol usually sits above ubiquinone in price and is sensitive to oxidation, so it needs stable encapsulation.
Solubilised formulations
Oil, syrup or micelle forms in which the molecule is already dissolved. In the cross-over study the water-soluble variant reached the highest uptake.
Downside: the range of products is wide and the studies are small. In the study named above, the syrup preparation was also the investigators' own test product. A label alone says little.
Add fat, split the dose
Coenzyme Q10 is fat-soluble. Taken with a meal that contains fat, considerably more can be absorbed than on an empty stomach.
Reviews also describe that uptake efficiency drops as the single dose rises. Splitting the amount across the day can therefore do more than switching to a more expensive form.
Before you spend more on the pricier form, check two free levers: are you taking it with a meal that contains fat? And are you taking one large single dose or spreading it out?
In that order, the question of form comes third, not first.
And now you know why I consider the ubiquinol question the most overrated question in this whole topic.
Covering a need or treating: same substance, two worlds
Here comes a distinction I make in every article of this series, because it explains almost every misunderstanding about supplements.
There are two completely different uses of the same substance. They carry the same name, they sit on the same shelf, and they have almost nothing to do with each other.
| Feature | Covering a need, the drugstore product | Therapeutic use, orthomolecular |
|---|---|---|
| Goal | Fill a suspected gap | Address a defined finding on purpose |
| Order of magnitude | Mostly low daily doses from online retail | Not something to fix in general, it depends on the findings and on concurrent medication. The ranges used in studies are named in the text and are not a specification for an individual case. |
| Supervision | None, self-purchase | Baseline lab, follow-up appointment, exit plan |
| Duration | Often open-ended, in practice a subscription | Time-limited, with a defined goal |
| Expected effect | A therapeutic effect is not to be expected from this | Can be clinically relevant in individual indications |
Coenzyme Q10 is excellent for showing this principle. In a rare, genetically caused coenzyme Q10 deficiency disorder, amounts far above anything on a drugstore shelf are used under close medical supervision. There, coenzyme Q10 is not understood as a supplement but as a targeted intervention. Important alongside that: coenzyme Q10 is not an authorised medicine in Germany. Such a use is an individual healing attempt in a confirmed, rare diagnosis and cannot be transferred to anyone else.
Same molecule, two worlds. One fills a suspected gap, the other is a medical intervention.
High doses are not a seal of quality and not a trick to prescribe yourself. A risk assessment names 1200 mg per day as the observed safe level of intake, and for higher amounts the authors said the data was explicitly not sufficient. The origin belongs to the picture: it was written by the US trade association of the supplement industry. For food supplements in Germany, the maximum daily amount proposed by the Federal Institute for Risk Assessment sits considerably below that. Anything above it comes from study protocols, and that belongs in medical hands and not in self-medication.
Therapeutic doses therefore belong under medical supervision, with a baseline value, an interim check and a clear plan for when to stop. Not only because every targeted intervention needs a frame in which you can tell whether it is doing anything, but also because coenzyme Q10 can interact with anticoagulants and with an ongoing blood pressure therapy.
Why this topic is more relevant today than fifty years ago
I am often asked whether this whole supplement boom is not simply an invention of the industry. My honest answer: partly yes, partly no.
Yes, because a great deal is sold that nobody needs. No, because some conditions have genuinely changed. Heavily processed foods deliver a lot of energy at low micronutrient density, and their share of the diet is high in Western countries. Whether, beyond that, the nutrient contents of fruit and vegetables have changed across the decades is methodologically contested, and I therefore do not use it as an argument.
And then there is one point that is especially clear with coenzyme Q10: some long-term medications can shift the nutrient balance. For proton pump inhibitors and for metformin, both prescription-only medicines that are well justified in their indication, a lower vitamin B12 status has been described. For diuretics, shifts in potassium and magnesium are discussed. And for statins, the coenzyme Q10 level. None of these points is an argument against these medicines, they are an argument for looking occasionally during long-term use, and for doing so with the practice that prescribed them.
Not because supplementation is fashionable, but because conditions have changed, targeted topping up can be justified more often today than it used to be. Targeted means: with a reason, with a measurement, with an end.
And now you know why on this topic I want to be neither a salesman nor a sceptic, but simply precise.
What else coenzyme Q10 is studied for, each with its evidence level
Coenzyme Q10 turns up in a great many guides. That is not because it would be a cure-all. It is because a molecule that runs along in the energy production of every cell can make itself noticed in many places when it gets scarce.
Even so, the data differs a lot from field to field. Here are the four most important ones, honestly sorted.
An international working group led by a Danish cardiologist randomised 420 people with moderate to severe heart failure to 100 mg of coenzyme Q10 three times daily or placebo, each on top of standard therapy, and followed them for two years.
After 16 weeks nothing showed up in the short-term endpoints. After two years, 15 percent of the coenzyme Q10 group reached the combined endpoint of major cardiovascular events, compared with 26 percent on placebo. All-cause mortality was also lower, 10 versus 18 percent.
The criticism belongs to the picture: this is a single trial of medium size, whose participants came from very different countries and healthcare settings. A result like this needs independent confirmation before it can become a standard.
And one request alongside it: heart failure is not a condition to experiment on yourself with a supplement. In this trial coenzyme Q10 was given on top of full standard therapy and under close monitoring. Coenzyme Q10 is not an authorised medicine in Germany, so this study result is not a treatment proposal. Anyone living with heart failure discusses this with their treating cardiology team and changes nothing about the existing medication.
Mortensen SA et al. JACC Heart Fail. 2014. DOI: 10.1016/j.jchf.2014.06.008| Field of use | What the data shows | How solid |
|---|---|---|
| Chronic heart failure | In one randomised trial with 420 people, fewer major cardiovascular events occurred over two years than on placebo, in each case on top of full standard therapy and under close monitoring | Medium: one randomised trial, independent confirmation still outstanding |
| Blood pressure in cardiometabolic disease | Meta-analysis of 26 studies with 1,831 people: systolic 4.77 mmHg lower, with a U-shaped curve and the largest effect at 100 to 200 mg daily | Moderate by GRADE for the systolic value, lower for the diastolic |
| Statin-associated muscle symptoms | Three meta-analyses with contradictory results, the most careful single trial with 600 mg ubiquinol found no effect | Inconsistent: no verdict possible |
| Migraine prophylaxis | Meta-analysis of two studies with 97 adults: no significant difference in frequency, duration or intensity of attacks | Weak: very small data base |
| Male fertility | Network meta-analysis: better forward motility of sperm, mean difference 5.28 percentage points | Weak to medium: surrogate marker, no pregnancy rates |
What stands here are results of published studies. They are not statements about what a food supplement can do. Coenzyme Q10 is not an authorised medicine in Germany, and it may be neither advertised nor used for the treatment or the prevention of a disease.
Heart failure belongs exclusively in cardiological care. Raised blood pressure too belongs in medical treatment and not with a capsule from online retail.
Blood pressure is worth a second look, because something interesting turns up there. The evaluation of 26 randomised trials found no linear relationship along the lines of “more is more", but a U-shaped one. The strongest effect sat in the range of 100 to 200 mg daily, and above that it flattened out again.
That is exactly the homeostasis I spoke about at the beginning. The body works in control loops, not in straight lines. More is not automatically better, and with some nutrients more is even worse. That is far more dramatic with selenium and with vitamin B6 than with coenzyme Q10. But the principle is the same.
When a molecule works in almost every cell, it sounds plausible that it could do something good everywhere. That plausibility is precisely the trap.
Broad responsibility in metabolism does not mean broad effectiveness as a capsule. One is biochemistry, the other has to be shown in trials. With coenzyme Q10 that has succeeded in some fields and not in others.
And now you know why I give a different answer for each of these fields instead of one answer for all of them.
The four lenses: why Q10 plays along everywhere at once
In clinical psychoneuroimmunology we look at a symptom through four lenses. With coenzyme Q10 it becomes especially clear why that is not an esoteric detour but simply cell biology.
Metabolism
Coenzyme Q10 is the electron ferryman in the respiratory chain. Without that transport step the cell can barely make ATP. It sits most densely where the energy demand is highest: in the heart muscle, in skeletal muscle, in liver and kidney. A bottleneck here could therefore make itself felt as weakness under load rather than in a conspicuous lab value. That is not established: the studies meant to test exactly this chain reach contradictory results, as described in the chapter on muscle symptoms.
Immune system
In its reduced form, coenzyme Q10 can donate electrons in the fatty environment of membranes and lipoproteins and thereby slow chain reactions of fat oxidation. Since oxidised fats can themselves trigger inflammatory signals, this process touches the immune system. That is biochemistry: cause and consequence are not cleanly separated in this field, and no authorised health claim exists for it in the EU.
Nervous system
Nerve cells are among the hungriest cells for energy there are and can barely throttle their demand. That is why coenzyme Q10 is studied in neurological questions. Human evidence for that is thin so far. The nocebo phenomenon shows the other direction: the nervous system helps decide how strongly a muscle signal registers at all.
Hormone system
The mevalonate pathway, in which coenzyme Q10 is built, also supplies the backbone for cholesterol. And cholesterol is the starting substance for cortisol, oestrogen, testosterone and vitamin D. That explains why an intervention at this one switch point raises so many questions. It does not mean statins would endanger these hormones, there is no solid evidence for that.
These four lenses explain why coenzyme Q10 shows up in such different contexts. They also explain why I stay cautious. A molecule that plays along everywhere is, for that very reason, hard to isolate.
This is not about a lab value. It is about whether you can climb stairs without doing the maths afterwards. Whether you can take your medication without asking yourself every morning what it is doing to you. Whether you trust your body again.
That is not a side topic. That is room to move.
Safety, interactions and the one warning that counts
Now the section I consider the most important. Please do not skip it, even though it sounds less exciting than the rest.
Warning 1: never stop your statin on your own
- The greatest risk in this whole topic lies not in the capsule but in the thought “then I will just leave the statin out". That expressly does not mean coenzyme Q10 is without consequence. The next three sections describe where it very much can matter: with anticoagulants, with ongoing blood pressure therapy, in pregnancy and breastfeeding.
- A British observational study followed 1,005 people after an acute coronary syndrome. Around 15.5 percent deviated from the prescribed high-intensity statin therapy in the first month. Muscle symptoms were one of the strongest predictors of that. Over a median follow-up of 16 months, this deviation was linked with roughly double the risk of major cardiovascular events and of death from any cause, with stopping and non-adherence weighing most heavily.
- Observational data does not prove causality, and honesty requires saying so. But the direction is clear enough to turn it into a plain request: if you have symptoms, speak to the doctor who prescribed the statin. There are ways to change dose, preparation or dosing rhythm.
- And one question that absolutely belongs in that conversation: did a medication get added in the weeks before the symptoms began? Some prescription-only agents, among them certain antibiotics, antifungals and lipid-lowering drugs from other groups, can raise the statin level in blood considerably and thereby trigger muscle symptoms that were not there for years. So take your complete medication list with you, including anything you take without a prescription.
Warning 2: vitamin K antagonists such as phenprocoumon and warfarin
- Coenzyme Q10 resembles vitamin K structurally. That is the basis for the concern that it could influence anticoagulation.
- The data is contradictory. A prospective observational study in 171 people on warfarin found an increased rate of self-reported bleeding events for coenzyme Q10, with a ratio of 3.69. A small randomised cross-over study with 24 stably adjusted people, by contrast, found no change in INR and no change in the warfarin dose needed over four weeks.
- My reading: a contradiction of this kind is not a free pass. Anyone taking a vitamin K antagonist discusses coenzyme Q10 with a doctor beforehand and has their INR monitored more closely. That is not a ban, that is care.
Warning 3: pregnancy, breastfeeding and pre-existing conditions
- For pregnancy and breastfeeding, solid safety data on coenzyme Q10 is missing. Missing data is not proof of harm, but it is also not proof of safety. In this phase of life every supplement belongs in a medical conversation.
- The same holds with relevant liver and kidney conditions and with several long-term medications at once, because interactions are harder to judge there.
- It holds in particular during chemotherapy or radiotherapy. Whether an additional intake of antioxidants can influence the effect of those treatments is professionally debated and not conclusively settled. There, taking it belongs exclusively in the hands of the treating oncology team and not on your own initiative.
- And for children and adolescents: every figure named here comes from studies in adults. There is no transferable data base for childhood and adolescence, so taking it belongs exclusively in paediatric hands there.
- On tolerability itself: a risk assessment found no dose dependency for reported complaints such as nausea, they were no more frequent at 1200 mg daily than at 60 mg. The authors named 1200 mg per day as the observed safe amount. The origin belongs with it: the first author worked at the Council for Responsible Nutrition, the US trade association of the supplement industry. For food supplements in Germany, the maximum daily amount proposed by the Federal Institute for Risk Assessment sits considerably lower.
Warning 4: blood pressure medication
- The meta-analysis of 26 trials suggests that coenzyme Q10 can lower systolic blood pressure. If that holds, the effect can add to an ongoing blood pressure therapy.
- Anyone taking blood pressure medication therefore discusses this with a doctor beforehand and measures more closely in the first weeks. Strikingly low readings, dizziness on standing up or light-headedness belong in an appointment promptly.
- This is not an argument against coenzyme Q10. It is an argument for taking a possible blood pressure effect seriously where it arrives at the wrong moment, and not only where it sounds useful.
This text does not replace a medical examination, a diagnosis or individual advice. All doses named here are figures from published studies and official assessments, not a recommendation for you.
If you notice new muscle pain, dark urine or marked weakness while on a statin, that is a reason to seek medical advice promptly, and not a reason to try it alone with a supplement.
And now you know why the sentence “Q10 cannot do any harm anyway" does not work as a starting point. There are situations that call for a closer look.
Three levers you can put in place today
No brands, no weekly plans, no protocol. Three things that lie in your hands.
Lever 1: first clarify whether it is the statin at all
- For two weeks, note when the symptoms appear, where exactly they sit and what makes them better or worse. Two sentences a day is enough.
- Take these notes into your appointment. They are worth more than any search engine, because they show your course and not the average.
- Ask explicitly whether a controlled pause or a controlled restart makes sense for you. In the single-patient trials that was exactly the route that brought clarity. In the primary care series across 50 practices, two thirds of those who completed the trial reported restarting their statin. In the London crossover trial, half of the participants were back on a statin six months later.
Lever 2: look instead of guessing, before you buy
- Coenzyme Q10 can be measured in plasma. Reviews name a range of roughly 0.40 to 1.91 micromoles per litre for healthy adults.
- Whether that measurement contributes anything in an individual case is open: the plasma value does not show how much arrives in the muscle, and there is no recognised threshold for it above which taking it would be indicated. It mainly shows whether anything arrived at all. I name the measurement here as an option, therefore, and not as a recommendation. It is a self-pay service, and whether it is worth it for you is something you decide after the conversation and not before.
- In the same step, talk about the obvious other explanations for muscle symptoms, such as vitamin D status, thyroid values, kidney values and the complete medication list. Which values make sense for you is decided by the doctor treating you, and that can also mean: none. With magnesium it belongs said that the serum value reflects a deficiency poorly, because the body holds that value constant for a long time.
Lever 3: if you try it, then with a goal and with an end
- Write down beforehand, in one sentence, what should change and how you would notice it. “Less pulling in the muscles when climbing stairs" is a goal. “Feeling better" is not.
- Set a follow-up appointment before you begin. Eight to twelve weeks is a usual period in the studies. After that you decide whether it continues.
- If you and your practice decide together on a time-limited attempt, the uptake studies say this much: coenzyme Q10 is fat-soluble, more can arrive with a meal that contains fat than on an empty stomach, and uptake efficiency drops as the single dose rises. What that means in your case belongs in an appointment, not in a blog article.
- And the request I cannot repeat often enough: the statin stays, as long as your doctor does not say otherwise.
And now you know why the most honest answer to “should I take coenzyme Q10 with my statin" is neither yes nor no, but: let us first look at what is actually going on with you.
Common questions about coenzyme Q10 and statins
What is coenzyme Q10 and what does it do in the body?
Coenzyme Q10 is a fat-soluble molecule that sits in almost every cell of your body.
Its main job is in the respiratory chain of the mitochondria, where it carries electrons from one complex to the next. Without that transport step the cell can barely make ATP, the energy currency of the body. Reviews also describe a second role: in its reduced form, coenzyme Q10 can donate electrons in the fatty environment of cell membranes and lipoproteins. That is biochemistry, and it describes what the molecule does in the laboratory. A health claim cannot be derived from it, and for coenzyme Q10 no such claim is authorised in the EU.
There is no official reference value for daily intake, because the body produces most of it and only a small part comes from food, mostly from organ meats, small oily fish, nuts and oils.
Should I take coenzyme Q10 while I am on a statin?
The data does not allow a clear yes or no, and anyone who claims otherwise is overstating it.
That statins lower the measured coenzyme Q10 level in blood is well supported by meta-analyses. Whether the muscle symptoms come from that is open: two meta-analyses found an improvement in symptoms with coenzyme Q10, a third found no difference from placebo.
A time-limited trial with medical supervision can be defensible when symptoms are present and the statin therapy would otherwise be at risk. It is not an automatic step for everyone taking a statin. The frame is what matters: never stop a statin on your own.
How much coenzyme Q10 was given alongside statins in studies?
In the 2025 meta-analysis the daily doses used in the seven included randomised trials ranged from 100 to 600 mg, over periods of 30 to 90 days.
One of the most careful single trials in confirmed statin myalgia used 600 mg ubiquinol daily for eight weeks and found no difference from placebo, even though the serum level rose fourfold in the process.
These figures are study data, not a recommendation. Which dose makes sense and is safe in an individual case belongs in a medical conversation, because pre-existing conditions, other medication and the goal of treatment all play into it.
What is the difference between ubiquinone and ubiquinol?
They are two states of the same molecule, not two different substances.
Ubiquinone is the oxidised form, ubiquinol the reduced one, meaning the one loaded with two extra electrons. The body converts them into each other constantly, and that is precisely their function in the respiratory chain.
Reviews describe that around 95 percent of the coenzyme Q10 circulating in blood is present as ubiquinol, regardless of which form was swallowed. In a randomised cross-over study with 21 healthy older people, ubiquinol was not statistically superior to ubiquinone in uptake.
Many bioavailability data also come from investigations by authors with manufacturer ties. That does not make them wrong, but it belongs in the picture.
Coenzyme Q10 effects: what is scientifically supported?
The evidence differs a great deal from one field to the next.
The field studied most is chronic heart failure. There, a randomised trial in 420 people over two years showed fewer major cardiovascular events in the coenzyme Q10 group. That single trial does not replace confirmation by others, and coenzyme Q10 is not something to take on your own for heart failure. In the trial it was given on top of full standard therapy and under close monitoring. A dose-response meta-analysis of 26 studies found a systolic blood pressure 4.77 mmHg lower in people with cardiometabolic disease, but rated the certainty of that evidence only as moderate.
In migraine, a meta-analysis of two studies found no supported benefit. In male fertility, a network meta-analysis points towards better forward motility of sperm, although without any statement on pregnancy rates. For muscle symptoms on statins, the meta-analyses contradict each other.
Does coenzyme Q10 have side effects?
Coenzyme Q10 is considered well tolerated.
A risk assessment reviewed the available clinical trials and found that reported complaints such as nausea or stomach pressure showed no dose dependency, they were no more frequent at 1200 mg daily than at 60 mg. The authors named 1200 mg per day as the observed safe level of intake, and said the data was not sufficient for higher amounts. That assessment came from authors at the US trade association of the supplement industry, though, and for food supplements in Germany the maximum daily amount proposed by the Federal Institute for Risk Assessment sits considerably below it.
Well tolerated does not mean without consequence. Possible interactions with vitamin K antagonists are relevant, and in pregnancy and breastfeeding solid data is missing. That is why taking it in those situations belongs in a medical conversation.
Does coenzyme Q10 lower cholesterol?
No, coenzyme Q10 is not a cholesterol-lowering agent.
It is built in the same metabolic pathway as cholesterol, the mevalonate pathway, but it does not act at the point where statins act. According to current data, there is no evidence that taking coenzyme Q10 meaningfully lowers the LDL value.
Anyone who swaps a statin for a supplement is swapping a well supported risk reduction for an unsupported hope. That is exactly the point where a harmless supplement can turn into a risk.
When should I take coenzyme Q10, in the morning or in the evening?
The fat content of the meal matters more than the time of day.
Coenzyme Q10 is a large, strongly fat-loving molecule, so its uptake in the gut is slow and limited. Reviews describe a peak blood level around six hours after intake and a half-life of about 33 hours. Taken with a meal that contains fat, considerably more can arrive than on an empty stomach.
The same reviews also show that uptake efficiency drops as the single dose rises. Splitting the amount across the day can therefore make more sense than one large dose. Discuss the split with the doctor who is treating you.
Can I have my coenzyme Q10 level measured?
Yes, coenzyme Q10 can be measured in plasma.
Reviews name a range of roughly 0.40 to 1.91 micromoles per litre for healthy adults. For context: a meta-analysis of eight placebo-controlled study arms found a value around 0.44 micromoles per litre lower under statins. That figure is a mean difference between two groups, however, not the distance of any single person from the lower limit.
The plasma value also does not reliably show how much coenzyme Q10 arrives in muscle or in the heart, because the molecule is transported inside lipoproteins. There is no recognised threshold for it above which taking it would be indicated. I name the measurement as an option, therefore, and not as a recommendation. It is a self-pay service, and whether it is worth it for you is something you decide after the medical conversation and not before.
Who should not take coenzyme Q10 without asking first?
Four groups should talk to a doctor beforehand.
First, people on vitamin K antagonists such as phenprocoumon or warfarin. A prospective observational study in 171 treated people linked coenzyme Q10 with more frequent self-reported bleeding events, while a small randomised study found no change in INR. The data is contradictory, and that alone is reason enough for caution and closer INR monitoring.
Second, people who are pregnant or breastfeeding, because solid safety data is missing. Third, people with relevant liver or kidney conditions and several long-term medications. And fourth, anyone considering stopping their statin because of this. That is the step with the greatest risk.
How this topic connects with the others
Coenzyme Q10 rarely stands alone. If you notice that a single building block does not answer the question, these paths lead further.
Supplements
The guide this article belongs to
You are hereWhen supplementing makes sense
Control loops, and why more is not better
Orthomolecular or supplement
Why the dose changes everything
Vitamin K2 and D3
The second topic with an anticoagulant warning
Energy and cofactors
Who else works in the respiratory chain
Glutathione
The water-soluble counterpart in cell protection
Omega-3 index
Measuring instead of guessing, on a second example
Strength training from 40
What makes muscles stronger than any capsule
Sources
- Banach M, Serban C, Ursoniu S et al. Statin therapy and plasma coenzyme Q10 concentrations, A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329-336. DOI: 10.1016/j.phrs.2015.07.008 [Meta-analysis, k=8]
- Qu H, Meng YY, Chai H et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. Eur J Med Res. 2018;23(1):57. DOI: 10.1186/s40001-018-0353-6 [Meta-analysis, k=12, n=1,776]
- Qu H, Guo M, Chai H et al. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018;7(19):e009835. DOI: 10.1161/JAHA.118.009835 [Meta-analysis, k=12, n=575]
- Kennedy C, Köller Y, Surkova E. Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis. Atherosclerosis. 2020;299:1-8. DOI: 10.1016/j.atherosclerosis.2020.03.006 [Meta-analysis, k=7, n=321, one authorship with an industry affiliation outside the coenzyme Q10 market]
- Kovacic S, Habicht SD, Eckert GP. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. J Nutr Sci. 2025;14:e72. DOI: 10.1017/jns.2025.10043 [Meta-analysis, k=7, n=389]
- Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329-335. DOI: 10.1016/j.atherosclerosis.2014.12.016 [RCT, n=41 of 120 screened]
- Howard JP, Wood FA, Finegold JA et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment (SAMSON). J Am Coll Cardiol. 2021;78(12):1210-1222. DOI: 10.1016/j.jacc.2021.07.022 [RCT, crossover, n=60]
- Herrett E, Williamson E, Brack K et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials (StatinWISE). BMJ. 2021;372:n135. DOI: 10.1136/bmj.n135 [RCT, n=200 n-of-1]
- Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms, A Good Idea, but… Adv Nutr. 2018;9(4):519S-523S. DOI: 10.1093/advances/nmy010 [Mechanism Review]
- Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 Supplementation in Aging and Disease. Front Physiol. 2018;9:44. DOI: 10.3389/fphys.2018.00044 [Review]
- Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006;40(5):445-453. DOI: 10.1080/10715760600617843 [Review, manufacturer-linked authorship]
- Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7 Suppl:S78-S88. DOI: 10.1016/j.mito.2007.03.003 [Review, manufacturer-linked authorship]
- Pravst I, Rodríguez Aguilera JC, Cortes Rodriguez AB et al. Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals. Nutrients. 2020;12(3):784. DOI: 10.3390/nu12030784 [RCT, crossover, n=21]
- Mortensen SA, Rosenfeldt F, Kumar A et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail. 2014;2(6):641-649. DOI: 10.1016/j.jchf.2014.06.008 [RCT, n=420, 2 years]
- Mortensen AL, Rosenfeldt F, Filipiak KJ. Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiol J. 2019;26(2):147-156. DOI: 10.5603/CJ.a2019.0022 [RCT, subgroup analysis]
- Zhao D, Liang Y, Dai S et al. Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2022;13(6):2180-2194. DOI: 10.1093/advances/nmac100 [Meta-analysis, k=26, n=1,831]
- Okoli GN, Rabbani R, Kashani HH et al. Vitamins and Minerals for Migraine Prophylaxis: A Systematic Review and Meta-analysis. Can J Neurol Sci. 2019;46(2):224-233. DOI: 10.1017/cjn.2018.394 [Meta-analysis, k=2, n=97]
- Chen Z, Hong Z, Wang S et al. Effectiveness of non-pharmaceutical intervention on sperm quality: a systematic review and network meta-analysis. Aging (Albany NY). 2023;15(10):4253-4268. DOI: 10.18632/aging.204727 [Systematic Review, network meta-analysis]
- Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (Ubiquinone). Regul Toxicol Pharmacol. 2006;45(3):282-288. DOI: 10.1016/j.yrtph.2006.05.006 [Review, risk assessment]
- Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007;27(9):1237-1247. DOI: 10.1592/phco.27.9.1237 [Cohort, n=171]
- Engelsen J, Nielsen JD, Hansen KFW. Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. Ugeskr Laeger. 2003;165(18):1868-1871. PMID: 12772396 [RCT, crossover, n=24]
- Turner RM, Yin P, Hanson A et al. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol. 2017;11(1):204-214. DOI: 10.1016/j.jacl.2016.12.007 [Cohort, n=1,005]
- Moschetti A, Dagda RK, Ryan RO. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. Nanomedicine. 2021;37:102439. DOI: 10.1016/j.nano.2021.102439 [In vitro, murine myotubes]
- Herrett E, Williamson E, Brack K et al. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technol Assess. 2021;25(16):1-62. DOI: 10.3310/hta25160 [RCT, n=200, full report]